Related Experiment Videos
[Effects of cefotaxime on the coagulation system, especially their dependence on vitamin K-related factors]
T Nishimura1, K Tabuki, T Motohiro
1Department of Pediatrics, Osaka Medical College.
Insights
Cefotaxime administration in children showed no adverse effects on peripheral blood counts or coagulation. Laboratory tests for protein induced by vitamin K deficiency or antagonist II (PIVKA II), hepaplastin test (HPT), prothrombin time (PT), and active partial thromboplastin time (APTT) remained normal.
Area of Science:
- Pediatric Pharmacology
- Hematology
- Clinical Chemistry
Context:
- Antibiotic use in pediatric populations requires careful monitoring of potential side effects.
- Assessing the impact of cefotaxime on hematological and hemostatic parameters is crucial for patient safety.
Purpose:
- To evaluate the effects of cefotaxime on peripheral blood counts and coagulation parameters in children.
- To determine if cefotaxime influences hematocrit, hemoglobin, platelet, or red blood cell counts.
- To assess cefotaxime's impact on coagulation markers including PIVKA II, HPT, PT, and APTT.
Summary:
- Administration of cefotaxime to 20 pediatric patients did not result in abnormal peripheral blood values.
- Coagulation system analysis revealed negative protein induced by vitamin K deficiency or antagonist II (PIVKA II) in all subjects.
- No significant changes in hepaplastin test (HPT), prothrombin time (PT), or active partial thromboplastin time (APTT) were observed, indicating no increased bleeding tendency.
Impact:
- This study suggests cefotaxime is safe regarding hematological and coagulation parameters in the pediatric population.
- Findings support the continued use of cefotaxime in children without significant hemostatic concerns.
- Provides valuable data for clinicians regarding the safety profile of cefotaxime in pediatric patients.
Abstract:
The authors administered cefotaxime to 20 children and studied laboratory parameters concerning peripheral blood: hemoglobin count, blood platelet count, red blood cell count, and hematocrit value, and the coagulation system: protein induced by vitamin K deficiency or by the presence of a vitamin K antagonist II (PIVKA II), hepaplastin test (HPT), prothrombin time (PT) and active partial thromboplastin time (APTT). The results obtained are summarized as follows: 1. Peripheral blood No abnormal values were observed. 2. Coagulation system (1) PIVKA II: In all cases, PIVKA II was negative. (2) HPT, PT and APTT: In all cases, no significant changes of these values which would suggest the tendency for prolonged bleeding were observed.